[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100120278":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":11,"locations":29,"responsibleParty":42,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL",null,[13],"Drug: AZD1386",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","AZD1386","1 dose of oral solution",[9],[21,25],{"name":22,"affiliation":23,"role":24},"Raj Chetty, MD","AstraZeneca R&D, CPU Alderley Park, UK","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":27,"role":28},"Lars Ståhle, MD","AstraZeneca R&D, Södertälje, Sweden","STUDY_CHAIR",[30],{"facility":31,"status":11,"city":32,"state":33,"zip":11,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":11},"Research Site","Macclesfield","CHESHIRE","United Kingdom","UK",{"type":37,"coordinates":38},"Point",[39,40],-2.12564,53.26023,{"lat":40,"lon":39},{"type":11,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":43,"oldOrganization":44},"Rolf Karlsten, MD, PhD, Medical Science Director, Emerging Analgesia, Neuroscience","AstraZeneca R&D Södertälje, Sweden","100120278","phase-1-investigation-of-rateextent-of-excretion-of-radioactivity-in-urinefaeces-after-oral-administration-of-14cazd1386-100120278",false,"NCT00832169","Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386","An Open, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD1386 to Healthy Male Volunteers","Inclusion Criteria:\n\n* Body Mass Index of 18 - 30 and weight of 50 to 100 kilos.\n* Healthy volunteer must have regular bowel movements (at least once daily)\n\nExclusion Criteria:\n\n* History of psychiatric or somatic disease\u002Fcondition, which may interfere with the objectives of the study as judged by the investigator.\n* A family history of short QT syndrome or sudden cardiac death amongst first degree relatives.\n* Any clinically important abnormalities in heart rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes.",true,"MALE","35 Years","50 Years",{"count":57,"type":58},6,"ESTIMATED","INTERVENTIONAL",[61],"PHASE1","The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD1386 in healthy male volunteers.",[64],"Pain",[64],"COMPLETED","2009-04-27",{"date":69,"type":58},"2009-04-28",{"date":71,"type":11},"2009-01",{"date":73,"type":74},"2009-02","ACTUAL",{"name":5,"class":6},1]